Oppenheimer Reiterates Outperform Rating on Biogen (BIIB): "continue to view SMA as an important franchise"
Tweet Send to a Friend
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $250.00 price target on Biogen (NASDAQ: BIIB)The analyst commented, "BIIB reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
